A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers

Journal of Infectious Diseases

Volumn 215, Issue 1, 2017, Pages 52-55

  Pierce, Kristen K ^a   Whitehead, Stephen S ^b   Kirkpatrick, Beth D ^a   Grier, Palmtama L ^c   Jarvis, Adrienne ^a   Kenney, Heather ^b   Carmolli, Marya P ^a   Reynolds, Cynthia ^a   Tibery, Cecilia M ^c   Lovchik, Janece ^c   Janiak, Anna ^c   Luke, Catherine J ^b   Durbin, Anna P ^c   Pletnev, Alexander G ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

flavivirus; vaccine; West Nile virus

Indexed keywords

ALANINE AMINOTRANSFERASE; NEUTRALIZING ANTIBODY; PLACEBO; RWNDEN430; UNCLASSIFIED DRUG; WEST NILE VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENGUE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLAVIVIRUS; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; LIVER FUNCTION TEST; MALE; MIDDLE AGED; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RASH; SEROCONVERSION; URINALYSIS; VIREMIA; WEST NILE FEVER; WEST NILE VIRUS; AGE; BLOOD; EPIDEMIC; GENETICS; IMMUNOLOGY; UNITED STATES;

ADULT; AGE FACTORS; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROCONVERSION; UNITED STATES; VACCINES, ATTENUATED; VIREMIA; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 85039761806     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/INFDIS/JIW501     Document Type: Article

References (15)

1. Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott Williams and Wilkins, 2001:1403–125.
2. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 2006; 57:181–94.
3. Petersen LR, Carson PJ, Biggerstaff BJ, Custer B, Borchardt SM, Busch MP. Estimated cumulative incidence of West Nile virus infection in US adults, 1999–2010. Epidemiol Infect 2013; 141:591–5.
4. Lindsey NP, Kuhn S, Campbell GL, Hayes EB. West Nile virus neuroinvasive disease incidence in the United States, 2002–2006. Vector Borne Zoonotic Dis 2008; 8:35–40.
5. Amanna IJ, Slifka MK. Current trends in West Nile virus vaccine development. Expert Rev Vaccines 2014; 13:589–608.
6. CDC. West Nile virus human infections reported to ArboNET, United States. http://www.cdc.gov/westnile/resourcepages/survresources.html. Accessed 8 May 2016.
7. Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci U S A 2002; 99:3036–41.
8. Pletnev AG, St. Claire M, Elkins R, Speicher J, Murphy BR, Chanock RM. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 2003; 314:190–5.
9. Pletnev AG, Swayne DE, Speicher J, Rumyantsev AA, Murphy BR. Chimeric West Nile/dengue virus vaccine candidate: Preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 2006; 24:6392–404.
10. Maximova OA, Speicher JM, Pletnev AG, et al. Assurance of neuroattenuation of a live vaccine against West Nile virus: A comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine. Vaccine 2014; 32:3187–97.
11. Hanley KA, Goddard LB, Pletnev AG, et al. Infectivity of West Nile/Dengue chimeric viruses for West Nile and Dengue mosquito vectors. Vector Borne Zoonotic Dis 2005; 5:1–10.
12. Durbin AP, Whitehead SS, Pletnev AG, et al. The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine 2013; 31:5772–7.
13. Davis CT, Ebel GD, Lanciotti RS, et al. Phylogenetic analysis of North American West Nile virus isolates, 2001–2004: evidence for the emergence of a dominant genotype. Virology 2005; 342:252–65.
14. Durbin AP, Karron RA, Whitehead SS, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine with a 30 nucleotide deletion in the 3’-untranslated region. Am J Trop Med Hyg 2001; 65:405–13.
15. McMullen AR, May FJ, Li L, et al. Evolution of new genotype of West Nile virus in North America. Emerg Infect Dis 2011; 17:785–93.